<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ikonomidis, I.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Vamvakou, G.</style></author><author><style face="normal" font="default" size="100%">Katsichti, P.</style></author><author><style face="normal" font="default" size="100%">Venetsanou, K.</style></author><author><style face="normal" font="default" size="100%">Stamatelopoulos, K.</style></author><author><style face="normal" font="default" size="100%">Papamichael, C.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, A.-M.</style></author><author><style face="normal" font="default" size="100%">Lekakis, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function</style></title><secondary-title><style face="normal" font="default" size="100%">Growth Factors</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">CRP</style></keyword><keyword><style  face="normal" font="default" size="100%">Endothelium</style></keyword><keyword><style  face="normal" font="default" size="100%">Granulocyte colony stimulating factor</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukins</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-46249116428&amp;doi=10.1080%2f08977190802090614&amp;partnerID=40&amp;md5=5ed91db95c76a4276850e4e086b58e16</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">26</style></volume><pages><style face="normal" font="default" size="100%">117 - 124</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Primary objective: Granulocyte-colony stimulating factor (G-CSF) is used for the mobilization of bone marrow and endothelial progenitor cells, though G-CSF-induced inflammation may cause endothelial dysfunction. We examined the effects of G-CSF on endothelium, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α) and anti-inflammatory cytokines namely interleukin 10 (IL-10). Research design: We studied 60 women with breast cancer, who were randomized to either subcutaneous G-CSF (5 μg/kg), o.d. for 5 days after adjuvant chemotherapy (n = 40) or placebo (n = 20). Experimental interventions: We measured flow-mediated dilatation (FMD%) of the brachial artery by ultrasonography, CRP, TNF-α, IL-10 and the ratio TNF-α/IL-10 blood levels before, 2-h and 5-days after the G-CSF or placebo treatment. Main outcomes and results: There was a greater increase of FMD, IL-10 and reduction of TNF-α/IL-10, 2 h and 5 days after the G-CSF treatment compared to placebo. Although, CRP and TNF-α were higher, TNF-α/IL-10 was lower at the end of G-CSF treatment compared to placebo. Improvement of FMD was related to changes of IL-10 and TNF-α/IL-10. Conclusions: Treatment with G-CSF improves endothelial function in vivo, possibly by shifting the balance between the pro- and anti-inflammatory cytokines.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :14Export Date: 21 February 2017</style></notes></record></records></xml>